Themis Medicare Ltd., a Mumbai-based pharmaceutical company with a 50-year legacy, has announced the launch of REMITHEM, a novel opioid injectable analgesic, in the Indian market. This groundbreaking medication is aimed at improving anesthesia induction, immediate post-operative care, and monitored anesthesia care. REMITHEM: A New Era in Opioid Analgesics Approved first in the USA in […]
Themis Medicare has been granted approval from the Drug Controller General of India (DCGI) for importing and commercialization of Remifentanil 1 mg/2mg Powder for Concentrate for Solution for Injection under the brand name REMITHEM. The drug has been authorized to be used as an analgesic medication for the induction and maintenance of general anesthesia during […]
